Literature DB >> 28150213

Artificial Antigen-Presenting Cells for Immunotherapies.

Alyssa L Siefert1, Tarek M Fahmy1, Dongin Kim2,3.   

Abstract

Artificial antigen-presenting cells (aAPCs) overcome many of the limitations of biologically based adoptive immunotherapy protocols. While these acellular systems can be designed with a variety of parameters, including material type, diameter, and proliferative signals for T cells, we outline methods to formulate and characterize a comprehensive polymeric microparticle aAPC platform. These aAPCs, which can be reproducibly fabricated in large quantities, efficiently stimulate antigen-specific T cell activation and proliferation by both paracrine cytokine signals and engagement of T cell surface proteins.

Entities:  

Keywords:  Immunotherapy; Microparticle; PLGA; Paracrine delivery; Polymer; aAPC

Mesh:

Substances:

Year:  2017        PMID: 28150213     DOI: 10.1007/978-1-4939-6646-2_21

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  4 in total

Review 1.  Nanovaccines for cancer immunotherapy.

Authors:  Yu Zhang; Shuibin Lin; Xiang-Yang Wang; Guizhi Zhu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-06-06

2.  Photochemical Treatment of Drosophila APCs Can Eliminate Associated Viruses and Maintain the APC Function for Generating Antigen-Specific CTLs Ex Vivo.

Authors:  Jun Ye; Chunxia Yang; Zeling Cai; Weixing Shi; Hong Yu
Journal:  Mediators Inflamm       Date:  2018-09-20       Impact factor: 4.711

Review 3.  Improving cancer immunotherapy through nanotechnology.

Authors:  Michael S Goldberg
Journal:  Nat Rev Cancer       Date:  2019-09-06       Impact factor: 60.716

4.  Evaluation of piggyBac-mediated anti-CD19 CAR-T cells after ex vivo expansion with aAPCs or magnetic beads.

Authors:  Li-Rong Yang; Lin Li; Ming-Yao Meng; Wen-Ju Wang; Song-Lin Yang; Yi-Yi Zhao; Run-Qing Wang; Hui Gao; Wei-Wei Tang; Yang Yang; Li-Li Yang; Li-Wei Liao; Zong-Liu Hou
Journal:  J Cell Mol Med       Date:  2020-11-22       Impact factor: 5.295

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.